Sunovion Pharmaceuticals Inc.

Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
Sunovion, a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the strength of the sun with innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.

Business Manufacturing and sales of pharmaceuticals
Address 84 Waterford Drive Marlborough, MA 01752
Telephone +1-508-481-6700
Facsimile +1-508-481-7683
Established January 1984

Product lineup

Major pharmaceutical productsTherapeutic indication
LATUDA® Atypical antipsychotic
APTIOM® Antiepileptic
UTIBRON NEOHALER® Long-acting muscarinic antagonist/
Long-acting beta2 agonist
SEEBRI NEOHALER® Long-acting muscarinic antagonist
ARCAPTA® NEOHALER® Long-acting beta2 agonist
BROVANA® Long-acting beta2 agonist
LUNESTA® Sedative hypnotic
XOPENEX HFA® Short-acting beta agonist